Works Cited

1. Schwartzberg LS. Potential practice-changing therapies in breast cancer: the year in review. Community Oncol. 2012;9(9S):540-543.

2. Brufsky MM, Dickerson SS. The diagnosis of breast cancer: transition from health to illness. Oncol Nurs Forum. 2006;33(6):1121-1127.

3. American Cancer Society. What Are the Key Statistics about Breast Cancer? Available at http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics. Last accessed July 13, 2016.

4. Byers T. Two decades of declining cancer mortality: progress with disparity. Ann Rev Pub Health. 2012;31:121-132.

5. Baltzell K, Wrensch MR. Strengths and limitations of breast cancer risk assessment. Oncol Nurs Forum. 2005;32(3):605-616.

6. Chen WY. Factors that Modify Breast Cancer Risk in Women. Available at http://www.uptodate.com/contents/factors-that-modify-breast-cancer-risk-in-women. Last accessed July 13, 2016.

7. Montgomery M. Uncertainty during breast cancer diagnostic evaluation: state of the science. Oncol Nurs Forum. 2010;37(1):77-83.

8. Lee CI, Elmore JG. Breast cancer screening. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 90-105.

9. American Cancer Society. What are the Key Statistics About Breast Cancer in Men? Available at http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics. Last accessed July 13, 2016.

10. National Cancer Institute Surveillance Epidemiology, and End Results Program. SEER Stat Fact Sheets: Female Breast Cancer. Available at http://seer.cancer.gov/statfacts/html/breast.html. Last accessed July 13, 2016.

11. Elmore JG. Risk Prediction Models for Breast Cancer Screening. Available at http://www.uptodate.com/contents/risk-prediction-models-for-breast-cancer-screening. Last accessed July 13, 2016.

12. Hutson PS. Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk. Oncol Nurs Forum. 2003;30(2):241-245.

13. Willett WC, Tamimi RM, Hankinson SE, Hazra A, Eliassen AH, Colditz GA. Nongenetic factors in the causation of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 211-267.

14. Clark PM. Nongenetic and heritable risk factors. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 10-24.

15. Khan SA. Management of other high risk patients. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 268-281.

16. Kimmick G, Seo PH. General Principals on the Treatment of Early-Stage and Locally Advanced Breast Cancer in Older Women. Available at http://www.uptodate.com/contents/general-principles-on-the-treatment-of-early-stage-and-locally-advanced-breast-cancer-in-older-women. Last accessed July 13, 2016.

17. Hammond MEH. Hormone Receptors in Breast Cancer: Clinical Utility and Guideline Recommendations to Improve Test Accuracy. Available at http://www.uptodate.com/contents/hormone-receptors-in-breast-cancer-clinical-utility-and-guideline-recommendations-to-improve-test-accuracy. Last accessed July 13, 2016.

18. Mahon SM. Risk factors for breast cancer. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011: 7-33.

19. National Cancer Institute. Breast Cancer Risk in American Women. Available at http://www.cancer.gov/types/breast/risk-fact-sheet. Last accessed July 13, 2016.

20. Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011;127(3):729-738.

21. Domchek SM, Peshkin BN, Schwartz MD, Isaacs C. Genetic testing and management of patients with hereditary breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 187-210.

22. National Cancer Institute. Genetics of Breast and Gynecologic Cancers (PDQ). Available at http://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq#section/_88. Last accessed July 13, 2016.

23. Hamilton R, Hurley K. Conditions and consequences of a BRCA mutation in young, single women of child bearing age. Oncol Nurs Forum. 2001;37(5):627-634.

24. Ashworth A. Inherited genetic factors and breast cancer. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 174-186.

25. Kerlikowske K, Cook A, Buist D, et al. Breast cancer risk by breast density, menopause and postmenopausal hormone therapy use.J Clin Oncol. 2010;28(24):3830-3834.

26. de Jong MM, Nolte IM, te Meerman GJ, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.J Med Genet. 2002;39:225-242.

27. Baumann SL. Family systems genetic illness model-breast cancer. Clin J Oncol Nurs. 2006;10(3):377-381.

28. Ashcroft PF, Coleman EA, Lange U, Enderlin C, Stewart CB. Obtaining family histories from patients with cancer. Clin J Oncol Nurs. 2007;11(1):119-124.

29. Erickson J, Lyon DE. Breast cancer in Cowden syndrome: manifestation of a familial cancer syndrome. Clin J Oncol Nurs. 2010;14(1):33-35.

30. Evans DG. Li-Fraumeni Syndrome. Available at http://www.uptodate.com/contents/li-fraumeni-syndrome. Last accessed July 13, 2016.

31. Parsons M. Li-Fraumeni syndrome and the role of the pediatric nurse practitioner. Clin J Oncol Nurs. 2011;15(1):79-87.

32. Steiner E, Klubert D, Knutson D. Assessing breast cancer risk in women. Am Fam Physician. 2008;78(12):1361-1366.

33. Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH. Upper-body morbidity after breast cancer incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;18(8 Suppl):2237-2249.

34. Kessler TA. Increasing mammography and cervical cancer knowledge and screening behaviors with an educational program. Oncol Nurs Forum. 2012;39(1):61-68.

35. Cox C, Oeffinger K, Montgomery M, Hudson MM, Mertens A, Whitton J. Determinants of mammography screening participation in adult childhood cancer survivors: results from the childhood cancer survivor study. Oncol Nurs Forum. 2009;36(3):335-344.

36. Crom DB, Hinds PS, Gattuso JS, Tyc V, Hudson MM. Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach. Oncol Nurs Forum. 2005;32(6):1131-1141.

37. Leahy Y. Second cancers in survivors of Hodgkin lymphoma: risks and recommendations. Clin J Oncol Nurs. 2008;12(3):437-442.

38. Jardines L, Goyal S, Royce M, Goldfarb SB. Stages 0 and I Breast Cancer. Available at http://www.cancernetwork.com/cancer-management/stages-0-I-breast/article/10165/1802570. Last accessed July 13, 2016.

39. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.

40. Nagaiah G, Hazard HW, Abraham J. Role of obesity and exercise in breast cancer survivors. Oncol. 2010;24(4):342-345.

41. Chowdhury R, Sinha B, Sankar MJ, et al. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis.Acta Paediatr. 2015;104(467):96.

42. Russell KM, Perkins SM, Zollinger TW, Champion VD. Sociocultural context of mammography screening use. Oncol Nurs Forum. 2006;33(1):105-112.

43. Vickers AJ. Prediction models in cancer care. CA Cancer J Clin. 2011;62(5):315-327.

44. Bucholtz J. Prevention strategies. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 25-44.

45. National Cancer Institute. Breast Cancer Risk Assessment Tool. Available at http://www.cancer.gov/bcrisktool/. Last accessed July 13, 2016.

46. Russo J. Breast Development and Morphology. Available at http://www.uptodate.com/contents/breast-development-and-morphology. Last accessed July 13, 2016.

47. Yackzan SG. Pathophysiology and staging. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 65-77.

48. Osborne MP, Boolbol SK. Breast anatomy and development. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 3-14.

49. Mohler ER III, Mehrara B. Clinical Features and Diagnosis of Peripheral Lymphedema. Available at http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-lymphedema. Last accessed July 13, 2016.

50. Muscari E. Lymphedema: responding to our patients' needs. Oncol Nurs Forum. 2004;31(5):905-912.

51. Ridner SH. Breast cancer lymphedema: pathophysiology and risk reduction guidelines. Oncol Nurs Forum. 2002;29(9):1285-1290.

52. Lawenda BD, Mondry TE, Johnstone PAS. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59(1):8-24.

53. Marrs J. Lymphedema and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11(1):19-21.

54. Martz CH, Kirby K. Symptom management. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 141-117.

55. McLaughlin SA. Lymphedema. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 590-601.

56. Mahon SM. Prevention and detection. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 35-64.

57. Yarbrough SS. Older women and breast cancer screening: research synthesis. Oncol Nurs Forum. 2005;31(1):E9-E15.

58. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev. 2008;(2):CD003373.

59. Machia J. Screening and early detection. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 45-57.

60. Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis and staging. Oncology. 2007;21(12):1521-1528.

61. Yackzan SG, Hatch J. Surgical management and reconstruction. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 79-92.

62. U.S. Preventive Services Task Force. Breast Cancer: Screening. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening1?ds=1&s=breast%20cancer. Last accessed July 13, 2016.

63. Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65(1):30-54.

64. Centers for Disease Control and Prevention. What is Breast Cancer Screening?. Available at http://www.cdc.gov/cancer/breast/basic_info/screening.htm. Last accessed July 13, 2016.

65. Helvie MA, Patterson SK. Imaging analysis: mammography. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 106-122.

66. Sung JS, Comstock CE. Image guided biopsy of non-palpable breast lesions. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 161-173.

67. Fraker T. Diagnosis and staging. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 58-77.

68. Weinstein SP, Roth SO. Imaging analysis: magnetic resonance imaging. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 133-148.

69. Alexandraki I, Mooradian AD. Barriers related to mammography use for breast cancer screening among minority women. J Natl Med Assoc. 2010;102(3):206-218.

70. Elkin EB, Snow JG, Leoce NM, Atoria CL, Schrag D. Mammography capacity and appointment wait times: barriers to breast cancer screening. Cancer Causes Control. 2012;23(1):45-50.

71. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351-376.

72. Allred DC. Pathology and biological features of premalignant breast disease. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010: 321-332.

73. Sabel MS. Overview of Benign Breast Disease. Available at http://www.uptodate.com/contents/overview-of-benign-breast-disease. Last accessed July 13, 2016.

74. American Cancer Society. Non-Cancerous Breast Conditions. Available at http://www.cancer.org/healthy/findcancerearly/womenshealth/non-cancerousbreastconditions/non-cancerous-breast-conditions-toc. Last accessed July 13, 2016.

75. Winkeljohn DL. Triple-negative breast cancer. Clin J Oncol Nurs. 2008;12(6):861-863.

76. Morrow M. Physical examination of the breast. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams &Wilkins; 2014: 25-28.

77. Pineault P. Breast cancer screening: women's experiences of waiting for further testing. Oncol Nurs Forum. 2007;34(4):847-853.

78. Solin LJ. Breast conservation treatment with radiation: an ongoing success story. J Clin Oncol. 2010;28(5):709-711.

79. Burstein H. Adjuvant Chemotherapy for HER2-Negative Breast Cancer. Available at http://www.uptodate.com/contents/adjuvant-chemotherapy-for-hormone-receptor-positive-or-negative-her2-negative-breast-cancer. Last accessed July 13, 2016.

80. Carey LA. Prognostic Molecular Profiles of Breast Cancer. Available at http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?18/2/18479. Last accessed July 13, 2016.

81. Pritchard KI. Adjuvant Endocrine Therapy for Non-Metastatic, Hormone Receptor-Positive Breast Cancer. Available at http://www.uptodate.com/contents/adjuvant-endocrine-therapy-for-non-metastatic-hormone-receptor-positive-breast-cancer. Last accessed July 13, 2016.

82. Maxwell C. Biomarker research in breast cancer. Clin J Oncol Nurs. 2010;149(6):771-783.

83. Loerzel VW, Hassey DK. Male breast cancer. Clin J Oncol Nurs. 2004;8(2):191-192.

84. Sedgwick EL. Imaging analysis: ultrasound. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 123-132.

85. Cancer Treatment Centers of America. MRI-Guided Breast Biopsy. Available at http://www.cancercenter.com/treatments/mri-guided-breast-biopsy/. Last accessed July 13, 2016.

86. Esserman L, Joe BN. Breast Biopsy. Available at http://www.uptodate.com/contents/breast-biopsy. Last accessed July 13, 2016.

87. Hassey DK. Targeted therapy and treatment of recurrent and metastatic breast cancer. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2003: 163-174.

88. American Cancer Society. Types of Biopsy Procedures. Available at http://www.cancer.org/treatment/understandingyourdiagnosis/examsandtestdescriptions/forwomenfacingabreastbiopsy/breast-biopsy-biopsy-types. Last accessed July 13, 2016.

89. Bleicher RJ. Management of the palpable breast mass. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 29-37.

90. Lucas JH, Cone L. Breast cyst aspiration. Am Fam Physician. 2003;68(10):1983-1987.

91. MedlinePlus. Breast Biopsy – Stereotactic. Available at https://www.nlm.nih.gov/medlineplus/ency/article/007433.htm#top. Last accessed July 13, 2016.

92. Collins LC, Laronga C, Wong JS. Breast Ductal Carcinoma In Situ: Epidemiology, Clinical Manifestations, and Diagnosis. Available at http://www.uptodate.com/contents/breast-ductal-carcinoma-in-situ-epidemiology-clinical-manifestations-and-diagnosis. Last accessed July 13, 2016.

93. Chung AP, Giuliano AE. Sentinel lymph node biopsy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 553-569.

94. Harlow SD, Weaver DL. Diagnosis, Staging and the Role of Sentinel Lymph Node Biopsy in the Nodal Evaluation of Breast Cancer: Indications and Outcomes. Available at http://www.uptodate.com/contents/sentinel-lymph-node-dissection-for-breast-cancer-indications-and-outcomes. Last accessed July 13, 2016.

95. Cody HS, Putas G. Axillary dissection. In: Harris JRE, Lippman M, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 570-578.

96. Bleiweiss IJ. Pathology of Breast Cancer. Available at http://www.uptodate.com/contents/pathology-of-breast-cancer. Last accessed July 13, 2016.

97. Sabel MS, Collins LC. Atypia and Lobular Carcinoma In Situ: High Risk Lesions of the Breast. Available at http://www.uptodate.com/contents/atypia-and-lobular-carcinoma-in-situ-high-risk-lesions-of-the-breast. Last accessed July 13, 2016.

98. Murray L, Reintgen M, Akman K, et al. Pleomorphic lobular carcinoma in situ: treatment options for a new pathologic entity.Clin Breast Cancer. 2012;12(1):76-79.

99. National Breast Cancer Foundation, Inc. Invasive Ductal Carcinoma (IDC). Available at http://www.nationalbreastcancer.org/invasive-ductal-carcinoma. Last accessed July 13, 2016.

100. Harvey JA. Unusual breast cancers: useful clues to expanding the differential diagnosis. Radiology. 2007;242(3):683-694.

101. Taghian A, El-Ghamry MN, Merajver SD. Inflammatory Breast Cancer: Clinical Features and Treatment. Available at http://www.uptodate.com/contents/inflammatory-breast-cancer-clinical-features-and-treatment. Last accessed June 21, 2016.

102. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Handbook. 7th ed. New York, NY: Springer; 2010.

103. National Breast Cancer Foundation, Inc. Inflammatory Breast Cancer. Available at http://www.nationalbreastcancer.org/inflammatory-breast-cancer. Last accessed June 28, 2016.

104. Sabel MS, Weaver DL. Paget Disease of the Breast. Available at http://www.uptodate.com/contents/paget-disease-of-the-breast. Last accessed July 13, 2016.

105. Carey LA. Molecular Intrinsic Subtypes of Breast Cancer. Available at http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?23/13/23774?source=HISTORY. Last accessed July 13, 2016.

106. Cleere DW. Triple-negative breast cancer: a clinical update. Commun Oncol. 2010;7(5):203-211.

107. Eisenberg S. Systemic therapy. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011: 113-140.

108. Hawk N, O'Regan R. Treatment of triple-negative breast cancer. Community Oncol. 2010;7(7):328-332.

109. Schwartzberg LS. New directions in the treatment of triple-negative breast cancer. Community Oncol. 2010;7(5):7-10.

110. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114-2122.

111. Press MF, Ma Y. HER2/ERBB2 testing: assessment of status for targeted therapies. In: Harris J, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 423-438.

112. Schiff R, Osborne CK, Fuqua SAW. Clinical aspects of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001: 408-430.

113. Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum. 2006;33(2):265-272.

114. American Joint Committee on Cancer. What is Cancer Staging? Available at https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx. Last accessed July 13, 2016.

115. American Joint Committee on Cancer. 8th Edition Publication Date Announced. Available at https://cancerstaging.org/About/news/Pages/8th-Edition-Publication-Date-Announced.aspx. Last accessed July 13, 2016.

116. Genestie C, Zafrani B, Asselain B, et al. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res. 1998;18(1B):571-576.

117. Morrow M, Golshan M. Mastectomy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 504-509.

118. Kwong A, Sable MS. Mastectomy: Indications, Types, and Concurrent Axillary Lymph Node Management. Available at http://www.uptodate.com/contents/mastectomy. Last accessed July 13, 2016.

119. Nahabedian M. Overview of Breast Reconstruction. Available at http://www.uptodate.com/contents/breast-reconstruction-in-women-with-breast-cancer. Last accessed July 13, 2016.

120. Sabel MS, Pierce L. Breast Conserving Therapy. Available at http://www.uptodate.com/contents/breast-conserving-therapy. Last accessed July 13, 2016.

121. Lynn J. Surgery techniques. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 81-89.

122. Nissen MJ, Swenson K, Kind EA. Quality of life after post mastectomy breast reconstruction. Oncol Nurs Forum. 2002;29(30): 547-553.

123. Hill O, White K. Exploring women's experiences of TRAM flap breast reconstruction after mastectomy for breast cancer. Oncol Nurs Forum. 2008;35(1):81-88.

124. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.

125. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143-1150.

126. Blichert-Toft M, Nielsen M, Düring M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672-681.

127. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.

128. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med. 1995;333:1444-1455.

129. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28(3):289-294.

130. van der Hage JA, Putter H, Bonnema J, et al. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer. 2003;39(15):2192-2199.

131. Buchholz TA, Hunt KK. Breast-conserving therapy: conventional whole breast irradiation. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2010: 507-521.

132. Perun J. Radiation therapy. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 110-133.

133. Jancin B. Brachytherapy doubles the risk of breast loss. Community Oncol. 2011;8(12):549-550.

134. Jenkins RW, Cannick L III, Harper JL. Use of MammoSite balloon brachytherapy for early-stage breast cancer. Community Oncol. 2011;8(1):37-40.

135. Mehrara BJ, Ho AY. Breast reconstruction. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 536-552.

136. National Comprehensive Cancer Network. NCCN Breast Cancer Guideline V.2.2016. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Last accessed July 13, 2016.

137. Baron R, Vaziri N. Reconstructive surgery. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 90-109.

138. Shockney DL, Tsangaris TT (eds). The Johns Hopkins Breast Cancer Handbook for Health Care Professionals. Boston, MA: Jones and Bartlett; 2008.

139. Shen J. Implications of post-mastectomy radiation therapy on optimal timing and approach for breast reconstruction. Community Oncol. 2010;7(12):548-560.

140. Dell DD, Weaver C, Kozempel J, Barsevick A. Recovery after transverse rectus abdominis myocutaneous flap breast construction surgery. Oncol Nurs Forum. 2008;35(2):189-196.

141. Stephens PA, Osowski M, Fidale MS, Spagnoli C. Identifying the educational needs and concerns of newly diagnosed patients with breast cancer after surgery. Clin J Oncol Nurs. 2008;12(2):253-258.

142. Johns Hopkins Medicine. Transverse Rectus Abdominis Myocutaneous (TRAM) Flap. Available at http://www.hopkinsmedicine.org/breast_center/treatments_services/reconstructive_breast_surgery/transverse_rectus_abdominis_myocutaneous_flap.html. Last accessed July 13, 2016.

143. Zenn MR. Free TRAM Breast Reconstruction. Available at http://emedicine.medscape.com/article/1273997-overview#a9. Last accessed July 13, 2016.

144. Kim JYS. Latissimus Flap Breast Reconstruction. Available at http://emedicine.medscape.com/article/1274087-overview. Last accessed July 13, 2016.

145. Casey MA, Mahon SM. Breast restoration options utilizing prostheses. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 93-103.

146. Kenefick AL. Patterns of symptom distress in older women after surgical treatment for breast cancer. Oncol Nurs J. 2006;33(2):327-335.

147. Ridner SH, Dietrich MS. Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum. 2008;35(1):57-63.

148. Armer J. Lymphedema. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 209-229.

149. Singer M. Lymphedema in breast cancer: dilemmas and challenges. Clin J Oncol Nurs. 2009;13(3):350-352.

150. McLaughlin SM, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213-5219.

151. Poage E, Singer M, Armer J, Poundall M, Shellabarger JM. Demystifying lymphedema: development of the lymphedema putting evidence into practice card. Clin J Oncol Nurs. 2008;12(6):951-964.

152. Radina ML, Armer JM, Culbertson SD, Dusold JM. Post-breast cancer lymphedema: understanding women's knowledge of their condition. Oncol Nurs Forum. 2004;31(1):97-104.

153. National Lymphedema Network. Position Statement: The Diagnosis and Treatment of Lymphedema. Available at http://www.lymphnet.org/pdfDocs/nlntreatment.pdf. Last accessed July 13, 2016.

154. Mohler ER III, Mehrara B. Clinical Staging and Conservative Management of Peripheral Lymphedema. Available at http://www.uptodate.com/contents/prevention-and-treatment-of-lymphedema. Last accessed July 13, 2016.

155. Ferraro CJ, Catanzaro PJ. Radiation therapy. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 105-111.

156. Pierce LJ. Techniques of Breast and Chest Wall Irradiation for Early Stage Breast Cancer. Available at http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?12/56/13185?source=see_link. Last accessed July 13, 2016.

157. Camporeale J. Basics of radiation treatment. Clin J Oncol Nurs. 2008;12(2):193-195.

158. Gordils-Perez J, Rawlins-Duell R, Kelvin JF. Advances in radiation treatment of patients with breast cancer. Clin J Oncol Nurs. 2003;7(6):629-636.

159. El-Ghamry MN, Taghian A. Radiation Techniques for Locally Advanced Breast Cancer. Available at http://hgp.gob.ec/index.html/uptodate/contents/UTD.htm?41/55/42873?source=related_link. Last accessed July 13, 2016.

160. Pierce LJ, Sabel MS. Breast Conserving Therapy. Available at http://www.uptodate.com/contents/breast-conserving-therapy. Last accessed July 13, 2016.

161. Vicini FA, Thomas JB, Shapiro-Wright H. Accelerated Partial Breast Irradiation. Available at http://androsma.5gbfree.com/contents/mobipreview.htm?12/27/12728?source=see_link. Last accessed July 13, 2016.

162. Hogel WP, Quinn AE, Heron DE. Advances in brachytherapy: new approaches to target breast cancer. Clin J Oncol Nurs. 2003;7(3):324-328.

163. Harris JR, Morrow M. Breast-conserving therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2014: 514-535.

164. Poirier P. The relationship of sick leave benefits, employment patterns, and individual characteristics of radiation therapy-related fatigue. Oncol Nurs Forum. 2006;33(3):593-601.

165. Iwamoto RR, Haas ML, Gosselin-Acomb T (eds). Manual for Radiation Oncology Nursing Practice and Education. 4th ed. Pittsburgh, PA: Oncology Nursing Society; 2012.

166. Escalante CP. Cancer-Related Fatigue: Prevalence, Screening and Clinical Assessment. Available at http://www.uptodate.com/contents/cancer-related-fatigue-prevalence-screening-and-clinical-assessment. Last accessed July 13, 2016.

167. Aistars J. The validity of skin care protocols followed by women with breast cancer receiving external radiation. Clin J Oncol Nurs. 2006;10(4):487-492.

168. Gosselin T, Schneider SM, Plambeck MA, Rowe K. A prospective randomized, placebo-controlled skin care study in women diagnosed with breast cancer undergoing radiation therapy. Oncol Nurs Forum. 2010;37(5):619-626.

169. Pierce LJ. Complications of Breast and Chest Wall Irradiation for Early Stage Breast Cancer. Available at http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?27/15/27903?source=see_link. Last accessed July 13, 2016.

170. Deutsch M, Flickinger JC. Compliance with adjuvant radiotherapy after surgery for primary breast cancer. Community Oncol. 2009;6(12):547-550.

171. Geddie P. Adjuvant therapy. In: Hassey DK (ed.). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 134-145.

172. Chen W. Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Prevention. Available at http://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention. Last accessed July 13, 2016.

173. Lexicomp Online. Available at http://online.lexi.com. Last accessed July 13, 2016.

174. BreastCancer.org. Fareston. Available at http://www.breastcancer.org/treatment/hormonal/serms/fareston. Last accessed July 13, 2016.

175. Kohli M, Lawrence TS, Reddy NM, et al. Principles of antineoplastic therapy. In: Rose M, DeVitaVT Jr, Lawrence TS, Wender RC (eds). Oncology in Primary Care. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.

176. Geddie P. Acute side effect management. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 189-197.

177. Versea L, Rosenzweig M. Hormonal therapy for breast cancer: focus on fulvestrant. Clin J Oncol Nurs. 2003;7(3):307-311.

178. Savage MI, Brown PH. Chemoprevention. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 282-308.

179. Rae JM. Pharmacogenomics of systemic therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 693-699.

180. Kuderer NM, Peppercorn J. CYP2D6 testing in breast cancer: ready for prime time? Oncology. 2009;23(14):1223-1232.

181. Harwood KV. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. Clin J Oncol Nurs. 2004;8(6):629-637.

182. Rimawi MF, Osborne CK. Adjuvant systemic therapy: endocrine therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 618-634.

183. Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol. 2010;14(1):41-47.

184. Litsas G. Nursing perspectives on fulvestarant for the treatment of postmenopausal women with metastatic breast cancer. Clin J Oncol Nurs. 2011;15(6):674-681.

185. Dienger MJ. Hormonal therapy. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 146-159.

186. Winters L, Habin K, Gallagher J. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs. 2007;11(3):433-439.

187. Gradishar WJ. Breast Cancer in Men. Available at http://www.uptodate.com/contents/breast-cancer-in-men. Last accessed July 13, 2016.

188. Listas G. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence. Oncol Nurs Forum. 2008;35(4):714-721.

189. Palmieri FM, Frye DK, Mahon SM. Current clinical issues in systemic therapy for metastatic breast cancer. Clin J Oncol Nurs. 2009;14(3):4-10.

191. Arteaga CL. Tyrosine kinase inhibitors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2010: 960-970.

192. Sheth S, Pal SK, Pegan MD. Treatment of HER2-overexpressing metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 960-973.

193. Tan SH, Wolff AC. Treatment of metastatic breast cancer: chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 929-959.

194. Dall P, Lenzen G, Göhler T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: results from an observational study in Germany. Geriatr Oncol. 2015;6(6):462-469.

195. Zucchini G, Bernardi A, Martoni A, Zamagni. Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer. Ann Oncol. 2013;24(1):264-265.

196. Albanell J, Ciruelos EM, Lluch A, Muñoz M, Rodriguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40(1):41-47.

197. U.S. Food and Drug Administration. FDA Approves New Treatment for Late-Stage Breast Cancer. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm340704.htm. Last accessed July 13, 2016.

198. Abraham J. Novel HER2-targeted agents for breast cancer therapy. Community Oncol. 2011;8(8):1-3.

199. U.S. Food and Drug Administration. FDA Approves Perjeta for Neoadjuvant Breast Cancer Treatment: First Drug Approved for Use in Preoperative Breast Cancer. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm370393.htm. Last accessed July 13, 2016.

200. Mittra A, Tripathy D. Looking ahead to rational combinational therapy. Community Oncol. 2012;9(2):40-44.

201. Murphy CG, Fortnier M. HER-2 positive breast cancer: beyond trastuzumab. Oncol. 2010;24(5):410-415.

202. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71.

203. Winkeljohn DL. Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 2010;14(4):461-466.

204. U.S. Food and Drug Administration. FDA Approves Ibrance for Postmenopausal Women with Advanced Breast Cancer. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm. Last accessed July 13, 2016.

205. ClinicalTrials.gov. Available at http://clinicaltrials.gov. Last accessed July 13, 2016.

206. Hurtig J. Managing patients with advanced and metastatic breast cancer. Clin J Oncol Nurs. 2010;14(3):313-323.

207. Dang C, Hudis CA. Adjuvant systemic chemotherapy in early breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 635-648.

208. Taylor CW, Muss HB. Adjuvant chemotherapy of breast cancer in the older patient. Oncology. 2010;24(7):608-613.

209. Chu E, DeVita VT. Physicians' Cancer Chemotherapy Drug Manual. 16th ed. Boston, MA: Jones & Bartlett; 2016.

210. Drugs@FDA. Label and Approval History: Doxorubicin Hydrochloride. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050629s022lbl.pdf. Last accessed July 13, 2016.

211. Palmieri FM, Myatt CV, Perez EA. Adjuvant trastuzumab for HER-2 positive early breast cancer: a review of clinical data with nursing implications. Clin J Oncol Nurs. 2010;14(3):326-336.

212. Frye D. Capecitabine-based combination therapy for breast cancer: implications for nurses. Oncol Nurs Forum. 2009;36(10):105-113.

213. Hawkins R, Grunberg S. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved outcomes.Clin J Oncol Nurs. 2009;13(1):54-64.

214. Polovich M, Olsen M, LeFebvre K (eds). Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 4th ed. Pittsburgh, PA: Oncology Nursing Society; 2014.

215. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.J Clin Oncol. 2011;29(31):4189-4198.

216. Donovan D. Management of peripheral neuropathy caused by microtubule inhibitors. Clin J Oncol Nurs. 2009;13(6):686-694.

217. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11(3):361-376.

218. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647-1656.

219. Sherwood G. Survivorship in Cancer. Torch: IWMF Newsletter. Available at http://www.iwmf.com/sites/default/files/docs/Torch%20October%202011.pdf. Last accessed July 13, 2016.

220. Myers JS. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum. 2012;39(1):E31-E40.

221. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliative Supportive Care. 2007;5(3):273-280.

222. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274-281.

223. Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer: current strategies and future directions. Clin J Oncol Nurs. 2011;15(1):63-71.

224. Evens K, Eschiti VS. Cognitive effects of cancer treatment: "chemo brain" explained. Clin J Oncol Nurs. 2009;13(6):661-666.

225. Staat K, Segatore M. The phenomenon of chemo brain. Clin J Oncol Nurs. 2005;9(6):713-721.

226. Schilder CM, Seynaeve C, Linn SC, et al. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol. 2010;76(2):133-141.

227. Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21(4):485-492.

228. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One. 2014;9(9):E108002.

229. Asher A. Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil. 2011;90:16-26.

230. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2013;17: 236-241.

231. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side effects on work ability: a focus group study. J Clin Nurs. 2010;19(9-10):1362-1370.

232. Boykoff N, Moieni M, Subramaniam SK. Confronting chemobrain: an in depth look at survivors' reports of impact on work, social network, and health care response. J Cancer Survivor. 2009;3(4):223-232.

233. Hurter B, Bush NJ. Cancer-related anemia. Clin J Oncol Nurs. 2007;11(3):349-359.

234. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;(7):CD006704.

235. Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients—an EAPC approach. Palliat Med. 2008;22(1):13-32.

236. U.S. Food and Drug Administration. Drug Approvals and Database. Available at http://www.fda.gov/Drugs/InformationOnDrugs/default.htm. Last accessed July 13, 2016.

237. Fuerst M. Relieving cancer-related fatigue: medication, exercise, and psychosocial interventions. Oncol Times. 2010;32(15):26-29.

238. Gelinas C, Fillion L. Factors related to persistent fatigue following completion of breast cancer treatment. Oncol Nurs Forum. 2004;31(2):269-278.

239. National Comprehensive Cancer Network. NCCN Cancer-Related Fatigue Guideline V 1.2016. Available at https://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. Last accessed July 13, 2016.

240. Harris J. Fatigue in chronically ill patients. Curr Opin Support Palliat Care. 2008;2(3):180-186.

241. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008;(2):CD006145.

242. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11:CD006145.

243. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CACancer J Clin. 2016;66:7-30.

244. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51-57.

245. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471-479.

246. National Cancer Institute. Male Breast Cancer Treatment (PDQ). Available at http://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq. Last accessed July 13, 2016.

247. Ravi A, Bang H, Karsif K, Nori D. Breast cancer in men: prognostic factors, treatment patterns, and outcome. Am J Men's Health. 2012;6:51-58.

248. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85(3):629-639.

249. Cimmino VM, Degnim AC, Sabel MS, et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol. 2004;86(2):74-77.

250. Goyal A, Horgan K, Kissin M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol. 2004;30(5): 480-483.

251. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992;65(2):252-254.

252. Wernberg JA, Yap J, Murekeyisoni C, et al. Multiple primary tumors in men with breast cancer diagnoses—a SEER database review. J Surg Oncol. 2009;99:16-19.

253. U.S. Food and Drug Administration. FDA Approves First Treatment for Breast Cancer with a Certain Inherited Genetic Mutation. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592347.htm. Last accessed February 28, 2018.

254. U.S. Food and Drug Administration. FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer. Available at https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm. Last accessed March 14, 2019.

Evidence-Based Practice Recommendations Citations

1. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(7):961-965. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/38701. Last accessed July 18, 2016.

2. American College of Obstetricians and Gynecologists. Breast Cancer Screening. Washington, DC: American College of Obstetricians and Gynecologists; 2011. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/34275. Last accessed July 18, 2016.

3. Horst KC, Haffty BG, Harris EE, et al. ACR Appropriateness Criteria: Postmastectomy Radiotherapy. Reston, VA: American College of Radiology; 2012. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/37924. Last accessed July 18, 2016.

4. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942-2962. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/47028. Last accessed July 18, 2016.

5. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-2269. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/48514. Last accessed July 18, 2016.

6. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/34606. Last accessed July 18, 2016.


Copyright © 2016 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.